Invasive group a streptococcal disease: Epidemiology, pathogenesis and management

Drugs

Volumn 72, Issue 9, 2012, Pages 1213-1227

  Steer, Andrew C ^a,b,c   Lamagni, Theresa ^d   Curtis, Nigel ^b,c   Carapetis, Jonathan R ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Clindamycin; Cloxacillin; Dicloxacillin; Flucloxacillin; Immune globulin; Methicillin resistant Staphylococcus aureus infections; Necrotising fasciitis; PathoGenesis; Septic shock; Streptococcal infections; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; CLOXACILLIN; DICLOXACILLIN; FLUCLOXACILLIN; IMMUNOGLOBULIN; PENICILLIN G; STREPTOCOCCUS ANTIGEN; VANCOMYCIN;

AGED; ANTIMICROBIAL THERAPY; BACTERIAL VIRULENCE; CHICKENPOX; DEBRIDEMENT; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GROUP A STREPTOCOCCAL INFECTION; HUMAN; HYPERBARIC OXYGEN; IMMUNOTHERAPY; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; MORTALITY; NECROTIZING FASCIITIS; NONHUMAN; PATHOGENESIS; PREGNANT WOMAN; PREVALENCE; REVIEW; SEX DIFFERENCE; SKIN DEFECT; STREPTOCOCCUS GROUP A; T LYMPHOCYTE; TOXIC SHOCK SYNDROME;

FEMALE; HUMANS; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 84862151705     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11634180-000000000-00000     Document Type: Review

References (152)

1. Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe streptococcus pyogenes disease in Europe. J Clin Microbiol 2008 Jul; 46 (7): 2359-67
2. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45: 853-62 (Pubitemid 47580376)
3. Stevens DL. Streptococcal toxic shock syndrome. Clin Microbiol Infect 2002 Mar; 8 (3): 133-6 (Pubitemid 34993777)
4. Katz AR, Morens DM. Severe streptococcal infections in historical perspective. Clin Infect Dis 1992 Jan; 14 (1): 298-307
5. Hribalová V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988 May; 108 (5): 772
6. Cone LA, Woodard DR, Schlievert PM, et al. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. NEngl J Med 1987 Jul 16; 317: 146-9 (Pubitemid 17092152)
7. Bartter T, Dascal A, Carroll K, et al. Toxic strep syndrome: a manifestation of group A streptococcal infection. Arch Intern Med 1988 Jun; 148 (6): 1421-4
8. Wheeler MC, Roe MH, Kaplan EL, et al. Outbreak of group A streptococcus septicemia in children: clinical, epidemiologic, and microbiological correlates. Jama 1991 Jul 24-31; 266: 533-7
9. Wong VK, Wright Jr HT. Group A beta-hemolytic streptococci as a cause of bacteremia in children. Am J Dis Child 1988 Aug; 142: 831-3
10. Christie CD, Havens PL, Shapiro ED. Bacteremia with group A streptococci in childhood. Am J Dis Child 1988 May; 142 (5): 559-61
11. Lamagni TL. The epidemiology of severe Streptococcus pyogenes disease in Europe. Helsinki: University of Helsinki, 2008
12. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987 Feb 19; 316: 421-7 (Pubitemid 17035568)
13. Stevens DL. The flesh-eating bacterium: what's next? J Infect Dis 1999 Mar; 179 Suppl. 2: S366-74
14. O'Grady K-A, Kelpie L, Andrews RA, et al. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Aust 2007; 186: 565-9 (Pubitemid 46929636)
15. Carapetis J, Robins-Browne R, Martin D, et al. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 1995 Nov; 21: 1220-7
16. Lamagni TL, Efstratiou A, Vuopio-Varkila J, et al. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Eurosurveillance 2005; 10 (9): 179-84
17. Zakikhany K, Degail MA, Lamagni TL, et al. Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill 2011; 16 (5): 19785
18. Norton R, Smith HV, Wood N, et al. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 2004 May; 119 Suppl.: 148-51 (Pubitemid 39004466)
19. Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000 May; 105 (5): E60
20. Tyrrell GJ, Lovgren M, Kress B, et al. Invasive group A streptococcal disease in Alberta, Canada (2000-2002). J Clin Microbiol 2005; 43: 1678-83
21. Kristensen B, Schonheyder HC. A 13-year survey of bacteraemia due to beta-haemolytic streptococci in a Danish county. J Med Microbiol 1995; 43 (1): 63-7
22. Siljander T, Lyytikainen O, Vahakuopus S, et al. Rapid emergence of emm84 among invasive Streptococcus pyogenes infections in Finland. J Clin Microbiol 2009 Feb 1; 47 (2): 477-80
23. Moses AE, Goldberg S, Korenman Z, et al. Invasive group A streptococcal infections, Israel. Emerg Infect Dis 2002; 8 (4): 421-6
24. Vlaminckx BJ, van Pelt W, Schouls LM, et al. Long-term surveillance of invasive group A streptococcal disease in the Netherlands, 1994-2003. Clin Microbiol Infect 2005; 11: 226-31 (Pubitemid 40352770)
25. Eriksson BK, Norgren M, McGregor K, et al. Group A streptococcal infections in Sweden: a comparative study of invasive and noninvasive infections and analysis of dominant T28 emm28 isolates. Clin Infect Dis 2003 Nov 1; 37 (9): 1189-93 (Pubitemid 37372507)
26. Eriksson BK, Andersson J, Holm SE, et al. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998 Dec; 27 (6): 1428-36 (Pubitemid 29242417)
27. Steer AC, Jenney AJ, Oppedisano F, et al. High burden of invasive beta-haemolytic streptococcal infections in Fiji. Epidemiol Infect 2008 May; 136 (5): 621-7 (Pubitemid 351472171)
28. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005 Jan 6; 352 (1): 39-47 (Pubitemid 40075679)
29. Le Hello S, Doloy A, Baumann F, et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. J Clin Microbiol 2010 Feb; 48 (2): 526-30
30. Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: a retrospective population-based study. JAMA 1993 Jan 20; 269: 384-9 (Pubitemid 23018078)
31. Bisno AL, Rubin FA, Cleary PP, et al. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles. Report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005 Oct 15; 41 (8): 1150-6
32. Laupland KB, Ross T, Church DL, et al. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. t ;. Clin Microbiol Infect 2006; 12: 224-30 (Pubitemid 43379322)
33. Passaro DJ, Smitht DS, Hett EC, et al. Invasive group A streptococcal infections in the San Francisco Bay area, 1989-99. Epidemiol Infect 2002; 129: 471-8 (Pubitemid 36157670)
34. Andersen MM, Rønne T. Group A streptococcal bacteraemias in Denmark 1987-89. J Infect 1995; 31: 33-7
35. Martin PR, Høiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22: 421-9 (Pubitemid 20266847)
36. O'Brien KL, Beall B, Barrett L, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35: 268-76 (Pubitemid 34800274)
37. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5 (11): 685-94 (Pubitemid 41505357)
38. Lamagni TL, Neal S, Keshishian C, et al. Predictors of death after severe Streptococcus pyogenes infection. Emerg Infect Dis 2009; 15: 1304-7
39. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14: 201-9 (Pubitemid 351213668)
40. Steer AC, Jenney AWJ, Kado J, et al. Invasive group A streptococcal disease in Fiji: prospective surveillance 2005-2007. Emerg Infect Dis 2009; 15: 216-22
41. Steer AC, Jenney AJ, Oppedisano F, et al. High burden of invasive beta-haemolytic streptococcal infections in Fiji. Epidemiol Infect 2008; 136 (5): 621-7 (Pubitemid 351472171)
42. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993 Jun; 16 (6): 792-800 (Pubitemid 23157983)
43. Ben Abraham R, Keller N, Vered R, et al. Invasive group A streptococcal infections in a large tertiary center: epidemiology, characteristics and outcome. Infection 2002; 30: 81-5 (Pubitemid 34293371)
44. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996 Aug 22; 335: 547-54 (Pubitemid 26272309)
45. Factor SH. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis 2003; 9: 970-7 (Pubitemid 36944518)
46. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008 Oct 1; 198 (7): 962-70
47. Tasher D, Stein M, Simõ es EAF, et al. Invasive bacterial infections in relation to influenza outbreaks, 2006-2010. Clin Infect Dis 2011 Dec 15; 53 (12): 1199-207
48. Lamagni TL, Neal S, Keshishian C, et al. Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004. Clin Microbiol Infect 2008; 4: 1002-9 (Pubitemid 352748840)
49. Navarro VJ, Axelrod PI, Pinover W, et al. A comparison of Streptococcus pyogenes (group A streptococcal) bacteremia at an urban and a suburban hospital; the importance of intravenous drug use. Arch Intern Med 1993; 153: 2679-84 (Pubitemid 23353578)
50. Sierra J, Sá nchez F, Castro P, et al. Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. Medicine (Baltimore) 2006; 85: 139-46 (Pubitemid 43829890)
51. Doctor A, Harper MB, Fleisher GR. Group A betahemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics 1995 Sep; 96 (3 Pt 1): 428-33
52. Falcone PA, Pricolo VE, Edstrom LE. Necrotizing fasciitis as a complication of chickenpox. Clin Pediatr (Phila) 1988 Jul; 27 (7): 339-43
53. Vugia DJ, Peterson CL, Meyers HB, et al. Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J 1996 Feb; 15: 146-50 (Pubitemid 26066494)
54. Brogan TV, Nizet V, Waldhausen JH, et al. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995 Jul; 14 (7): 588-94
55. Wilson GJ, Talkington DF, Gruber W, et al. Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin Infect Dis 1995 May; 20 (5): 1333-8
56. Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999 Apr; 103: 783-90 (Pubitemid 29274472)
57. Cowan MR, Primm PA, Scott SM, et al. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med 1994 Apr; 23 (4): 818-22
58. Bradley JS, Schlievert PM, Sample Jr TG. Streptococcal toxic shock-like syndrome as a complication of varicella. Pediatr Infect Dis J 1991 Jan; 10 (1): 77-9
59. Tyrrell GJ, Lovgren M, Kress B, et al. Varicella-associated group A streptococcal disease in Alberta, Canada 2000-2002. Clin Infect Dis 2005; 40: 1055-7 (Pubitemid 40418317)
60. Chuang I, Van Beneden C, Beall B, et al. Network ABCSEIP. Population-based surveillance for postpartum invasive group A Streptococcus infections, 1995-2000. Clin Infect Dis 2002 Sep 15; 35 (6): 665-70 (Pubitemid 35024725)
61. Deutscher M, Lewis M, Zell ER, et al. Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B Streptococcus infections among pregnant and postpartum women. Clin Infect Dis 2011 Jul 15; 53 (2): 114-23
62. Khan KS, Wojdyla D, Say L, et al.WHOanalysis of causes of maternal death: a systematic review. Lancet 2006 Apr 1; 367 (9516): 1066-74
63. Centre for Maternal and Child Enquiries and Royal College of Obstetricians and Gynaecologists. CMACE/RCOG joint guideline: management of women with obesity in pregnancy. 2010 Mar [online]. Available from URL: http://www.rcog.org.uk/files/rcog-corp/CMACERCOG JointGuidelineManagementWomenObesityPregnancya.pdf [Accessed 2012 Feb 1]
64. Miyairi I, Berlingieri D, Protic J, et al. Neonatal invasive group A streptococcal disease: case report and review of the literature. Pediatr Infect Dis J 2004; 23 (2): 161-5 (Pubitemid 38222791)
65. Mahieu LM, Holm SE, Goossens HJ, et al. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995 Dec; 127 (6): 987-9 (Pubitemid 26003299)
66. Health Protection Agency Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. Commun Dis Public Health 2004; 7: 354-61
67. Curtis N. Invasive group A streptococcal infection. Curr Opin Infect Dis 1996; 9: 191-2
68. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989 Jul; 2: 285-314 (Pubitemid 19181596)
69. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000 Jul; 13: 470-511 (Pubitemid 30452618)
70. Hasty DL, Ofek I, Courtney HS, et al. Multiple adhesins of streptococci. Infection and Immunity 1992; 60 (6): 2147-52
71. Horstmann RD, Sievertsen HJ, Leippe M, et al. Role of fibrinogen in complement inhibition by streptococcal M protein. Infect Immun 1992 Dec; 60: 5036-41
72. Wessels MR, Moses AE, Goldberg JB, et al. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991; 88: 8317-21 (Pubitemid 21915347)
73. Ji Y, McLandsborough L, Kondagunta A, et al. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996 Feb; 64 (2): 503-10 (Pubitemid 26032821)
74. Proft T, Sriskandan S, Yang L, et al. Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis 2003 Oct; 9 (10): 1211-8 (Pubitemid 37210560)
75. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002Mar; 2 (3): 156-62 (Pubitemid 34462450)
76. Curtis N. Kawasaki disease and toxic shock syndrome: at last the etiology is clear? Adv Exp Med Biol 2004; 549: 191-200 (Pubitemid 38968197)
77. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995 Jul; 8 (3): 411-26
78. Petersson K, Forsberg G, Walse B. Interplay between superantigens and immunoreceptors. Scand J Immunol 2004 Apr; 59 (4): 345-55 (Pubitemid 38482518)
79. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000 Jan; 13 (1): 16-34 (Pubitemid 30039341)
80. Miethke T, Wahl C, Heeg K, et al. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992 Jan 1; 175 (1): 91-8
81. Facklam R, Beall B, Efstratiou A, et al. emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis 1999; 5 (2): 247-53 (Pubitemid 29200623)
82. Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009; 9: 611-6
83. HPA. Group A streptococcal infections: fourth update on seasonal activity, 2008/09. Health Protection Report. 2009 [online]. Available from URL: http://www.hpa.org. uk/hpr/archives/2009/news2909.htm#gas0809 [Accessed 2012 Feb 1]
84. Holm SE, Norrby A, Bergholm AM, et al. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166: 31-7
85. Rogers S, Commons R, Danchin MH, et al. Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group a streptococcus infections. J Infect Dis 2007 Jun 1; 195 (11): 1625-33 (Pubitemid 46799220)
86. Shea PR, Beres SB, Flores AR, et al. Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci USA 2011 Mar 22; 108 (12): 5039-44
87. Bessen DE, Carapetis JR, Beall B, et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000 Oct; 182: 1109-16
88. Chelsom J, Halstensen A, Haga T, et al. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994 Oct 22; 344: 1111-5 (Pubitemid 24317630)
89. Giuliano A, Lewis Jr F, Hadley K, et al. Bacteriology of necrotizing fasciitis. Am J Surg 1977 Jul; 134 (1): 52-7 (Pubitemid 8148522)
90. Wall DB, de Virgilio C, Black S, et al. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg 2000 Jan; 179 (1): 17-21 (Pubitemid 30126003)
91. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 1997 Jul; 103 (1): 18-24 (Pubitemid 27314183)
92. Dahl PR, Perniciaro C, Holmkvist KA, et al. Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J Am Acad Dermatol 2002 Oct; 47 (4): 489-92
93. Ward RG, Walsh MS. Necrotizing fasciitis: 10 years' experience in a district general hospital. Br J Surg 1991 Apr; 78: 488-9
94. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995 Jul-Sep; 1: 69-78
95. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992 Jan; 14: 2-11
96. Kevy SV, Lowe BA. Streptococcal pneumonia and empyema in childhood. N Engl J Med 1961; 264: 738-43
97. Brothers TE, Tagge DU, Stutley JE, et al. Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J Am Coll Surg 1998 Oct; 187 (4): 416-21 (Pubitemid 28467618)
98. Zittergruen M, Grose C. Magnetic resonance imaging for early diagnosis of necrotizing fasciitis. Pediatr Emerg Care 1993 Feb; 9 (1): 26-8 (Pubitemid 23088569)
99. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol 1998 Mar; 170 (3): 615-20 (Pubitemid 28106647)
100. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis: the use of frozen-section biopsy. N Engl J Med 1984 Jun 28; 310 (26): 1689-93 (Pubitemid 14083438)
101. Wong CH, Wang YS. The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis 2005 Apr; 18 (2): 101-6
102. Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004 Jul; 32 (7): 1535-41
103. No authors listed. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993 Jan 20; 269: 390-1
104. Reingold AL, Hargrett NT, Shands KN, et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 1982 Jun; 96 (6 Pt 2): 875-80 (Pubitemid 12088887)
105. Catena F, La Donna M, Ansaloni L, et al. Necrotizing fasciitis: a dramatic surgical emergency. Eur J Emerg Med 2004; 11 (1): 44-8
106. Stevens DL. The toxic shock syndromes. Infect Dis Clin North Am 1996 Dec; 10 (4): 727-46 (Pubitemid 27011222)
107. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003; 96 (10): 968-73 (Pubitemid 38281664)
108. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999 Dec; 18 (12): 1096-100
109. Stevens DL, Gibbons AE, Bergstrom R, et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988 Jul; 158: 23-8
110. Mascini EM, Jansze M, Schouls LM, et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001; 18: 395-8 (Pubitemid 33016357)
111. Sriskandan S, McKee A, Hall L, et al. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997; 40 (2): 275-7 (Pubitemid 27394023)
112. Herbert S, Barry P, Novick RP. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect Immun 2001; 69 (5): 2996-3003 (Pubitemid 32332193)
113. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981 May; 67 (5): 1249-56 (Pubitemid 11099338)
114. Craig WA, Vogelman B. The postantibiotic effect. Ann Intern Med 1987 Jun; 106 (6): 900-2 (Pubitemid 17078987)
115. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003 Aug; 85-A (8): 1454-60 (Pubitemid 36951128)
116. Bilton BD, Zibari GB, McMillan RW, et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998 May; 64 (5): 397-400
117. Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37 (3): 166-72 (Pubitemid 40372838)
118. Muller MP, McGeer A, Low DE, Ontario Group A Streptococcal Study. Successful outcome in six patients treated conservatively for suspected necrotizing fasciitis (NF) due to group A streptococcus (GAS) [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001 Dec 16-19; Chicago (IL)
119. Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002; (1): CD001090
120. Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 2001 Oct; 7 (5): 354-61 (Pubitemid 33064366)
121. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64: 5395-8 (Pubitemid 26404008)
122. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156: 3057-64 (Pubitemid 126660657)
123. Andersson U, Chauvet JM, Skansen-Saphir U, et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. J ImmunolMethods 1994; 175: 201-13
124. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003 Aug 1; 37: 333-40 (Pubitemid 36976489)
125. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28: 800-7 (Pubitemid 29169419)
126. Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009; 49: 1369-76
127. Valiquette L, Low DE, McGeer AJ. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest. Clin Infect Dis 2009; 49: 1377-9
128. Orbach H, Katz U, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29 (3): 173-84 (Pubitemid 43041668)
129. Curtis N. Non-steroidal anti-inflammatory drugs may predispose to invasive group A streptococcal infections. Arch Dis Child 1996 Dec; 75 (6): 547 (Pubitemid 27008224)
130. Zerr DM, Rubens CE. NSAIDS and necrotizing fasciitis. Pediatr Infect Dis J 1999 Aug; 18 (8): 724-5 (Pubitemid 29382470)
131. Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995 Oct; 21 (4): 977-80
132. Ford LM, Waksman J. Necrotizing fasciitis during primary varicella. Pediatrics 2000 Jun; 105 (6): 1372-3; author reply 1373-5
133. Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001 May; 107 (5): 1108-15 (Pubitemid 32440619)
134. Forbes N, Rankin AP. Necrotizing fasciitis and non steroidal anti-inflammatory drugs: a case series and review of the literature. N Z Med J 2001 Jan 26; 114 (1124): 3-6 (Pubitemid 32125553)
135. Rimailho A, Riou B, Richard C, et al. Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs. J Infect Dis 1987 Jan; 155 (1): 143-6 (Pubitemid 17225098)
136. Brun-Buisson CJ, Saada M, Trunet P, et al. Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1985 Jun 15; 290 (6484): 1786 (Pubitemid 15059214)
137. Krige JE, Spence RA, Potter PC, et al. Necrotising fasciitis after diflunisal for minor injury. Lancet 1985 Dec 21-28; 2 (8469-70): 1432-3 (Pubitemid 16138591)
138. Cockerill 3rd FR. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children[comment]. Pediatrics 1998; 101: 136-40
139. Huang YC, Hsueh PR, Lin TY, et al. A family cluster of streptococcal toxic shock syndrome in children: clinical implication and epidemiological investigation. Pediatrics 2001 May; 107 (5): 1181-3
140. Schwartz B, Elliott JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992 Aug; 15 (2): 277-84
141. Gamba MA, Martinelli M, Schaad HJ, et al. Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997 Jun; 24 (6): 1118-21 (Pubitemid 27249010)
142. Stromberg A, Romanus V, Burman LG. Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. J Infect Dis 1991 Sep; 164 (3): 595-8
143. Auerbach SB, Schwartz B, Williams D, et al. Outbreak of invasive group A streptococcal infections in a nursing home: lessons on prevention and control. Arch Intern Med 1992 May; 152 (5): 1017-22
144. Public Health Agency for Canada. Guidelines for the prevention and control of invasive group A streptococcal diseases. Can Commun Dis Rep 2006; 52 (32): 1-26
145. Robinson KA, Rothrock G, Phan Q, et al. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis 2003 Apr; 9: 443-7 (Pubitemid 37070410)
146. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention [published erratum appears in Clin Infect Dis 2003 Jan 15; 36 (2): 243]. Clin Infect Dis 2002 Oct 15; 35: 950-9
147. Carapetis JR. Current issues in managing group A streptococcal infections. Adv Exp Med Biol 2004; 549: 185-90 (Pubitemid 38968196)
148. Smith A, Lamagni TL, Oliver I, et al. Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis 2005; 5 (8): 494-500 (Pubitemid 41022025)
149. Daneman N, Green KA, Low DE, et al. Surveillance for hospital outbreaks of invasive group a streptococcal infections in Ontario, Canada, 1992 to 2000. Ann Intern Med 2007; 147: 234-41 (Pubitemid 351664579)
150. Ministere de la Sante et des Solidarites. Comite technique des infections nosocomiales et des infections liees aus soins. Guide pour la prevention et l'investigation des infections hospitalieres a Streptococcus pyogenes. Paris: Ministere de la Sante et des Solidarites, 2006
151. Health Protection Surveillance Centre. Invasive group A streptococcus sub-committee. The management of invasive group A streptococcal infections in Ireland. Dublin: HPSC, 2006
152. Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK. J Infect 2012 Jan; 64 (1): 1-18